Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Endonovo Therapeutics Inc (OTCQB:ENDV.PK)

0.075
Delayed Data
As of 1:29pm ET
 -0.0049 / -6.13%
Today’s Change
0.05
Today|||52-Week Range
2.50
-94.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$8.1M

Company Description

Endonovo Therapeutics, Inc. is a biotechnology company developing off the shelf regenerative products that no longer require the injection of stem cells. The company's first platform Cell Free Therapeutics harnesses the biological secretions of cells to create therapies that can be immediately administered following injuries or to treat acute and chronic diseases. Its second platform is the development of non invasive, bioelectronics to stimulate the body's natural repair system to treat injuries and inflammatory diseases. Endonovo Therapeutics was founded on May 26, 2011 and is headquartered in Woodland Hills, CA.

Contact Information

Endonovo Therapeutics, Inc.
6320 Canoga Avenue
Woodland Hills California 91367
P:(800) 701-1223
Investor Relations:
18007011223108

Employees

Shareholders

Individual stakeholders39.63%
Mutual fund holders--
Other institutional--

Top Executives

Alan Brian CollierChairman, CEO, CFO & Secretary
Michael Scott MannPresident & Executive VP-Shareholder Relations
Donald J. CalabriaChief Operating Officer
Randolph M. JohnsonExecutive Vice President-Clinical Development
Leonard MakowkaChief Medical Officer